| Dapagliflozin Propanediol/ Metformin HCl |
Tablet (Extended Release) |
I (Basket- 20 mesh) |
100 |
Phosphate Buffer, pH 6.8 |
1000 |
Dapagliflozin: 5, 10, 15, 20, 30 and 45 minutes: Metaformin: 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours |
2015/08/27 |
| Dapagliflozin/Saxagliptin HCl |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/08/27 |
| Daprodustat |
Tablet |
II (Paddle) |
50 |
30 mM Phosphate Buffer, pH 6.8 |
500 for 1 mg; 900 for 2, 4, 6 and 8 mg |
5, 10, 15, 20, 25, 30, 45 and 60 |
2024/05/31 |
| Dapsone |
Tablet |
|
|
Refer to USP |
|
|
2010/12/23 |
| Dapsone |
Gel (Topical) |
|
|
Develop a method to characterize in vitro release |
|
|
2016/07/28 |
| Daridorexant HCl |
Tablet |
II (Paddle) |
75 |
pH 1.2 (NaCl/HCl) |
900 |
5, 10, 15 and 30 |
2023/05/18 |
| Darifenacin Hydrobromide |
Tablet (Extended Release) |
I (Basket) |
100 |
0.01N HCl |
900 |
1, 4, 8, 12, 16, 20 and 24 hours |
2006/01/20 |
| Darolutamide |
Tablet |
II (Paddle) |
75 |
1% sodium lauryl sulfate (SLS) in 0.01N HCl |
1000 |
15, 30, 45, 60, 75 and 90 |
2020/01/30 |
| Darunavir Ethanolate |
Oral Suspension |
II (Paddle) |
75 |
0.05% Polysorbate 20 in 0.05M Phosphate Buffer, pH 6.8 |
900 |
5, 10, 15, 20, 30 and 45 |
2015/06/25 |
| Darunavir Ethanolate |
Tablet |
II (Paddle) |
75 |
2% Tween-20 in 0.05 M Sodium Phosphate Buffer, pH 3.0 |
900 |
10, 20, 30, and 45 |
2007/09/13 |
| Darunavir(Drv)/Cobicistat (Cobi)/Emtricitabine (Emt)/Tenofovir Alafenamide Fumarate (Taf) |
Tablet |
II (Paddle) |
75 |
Drv: 0.05 M Sodium Phosphate Buffer, pH 3.0, 2% Tween 20; For Cobi, Emt and Taf: Citrate Phosphate Buffer, pH 4.2 |
900 |
Drv: 10, 15, 20, 30 and 45; For Cobi, Emt and Taf: 5, 10, 15, 20 and 30 |
2022/07/07 |
| Dasabuvir Na/ Ombitasvir/Paritaprevir/Ritonavir |
Tablet (Extended Release) |
III (Reciprocating Cylinder [40 mesh (for bottom and top of the inner tube)] |
25 dpm |
15 mM hexadecyltrimethylammonium bromide (CTAB) in 0.03M Sodium Phosphate Buffer, pH 6.8 |
250 |
Ombitasvir/ Paritaprevir/ Ritonavir: 10, 15, 20, 30, 45, 60 and 90 minutes;Dasabuvir: 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24 hours |
2016/10/20 |
| Dasatinib |
Tablet |
II (Paddle) |
60 |
pH 4.0 Acetate buffer containing 1% Triton X-100 |
1000 |
10, 15, 30 and 45 |
2009/10/30 |
| Deferasirox |
Tablet |
II (Paddle) |
75 |
0.5% Tween 20 in Phosphate Buffer, pH 6.8 |
900 |
5, 10, 15, 20 and 30 |
2016/03/17 |
| Deferasirox |
Tablet (for Oral Suspension) |
II (Paddle) |
50 |
Phosphate buffer pH 6.8 with 0.5% Tween 20 |
900 |
10, 20, 30 and 45 |
2006/06/21 |
| Deferasirox |
Granule |
II (Paddle) |
75 |
Phosphate Buffer, pH 6.8 with 0.5% Tween 20 |
900 |
5, 10, 15, 20 and 30 |
2017/11/02 |
| Deferiprone |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Deferiprone (1 GM) |
Tablet |
I (Basket) |
100 |
Acidic Stage: 0.1 N HCl, Buffer Stage: 0.05 M Phosphate buffer, pH 6.8. |
|
Acid Stage: 2 hours; Buffer Stage: 1, 2, 3 and 4 hours |
2022/07/07 |
| Deflazacort |
Suspension |
II (Paddle) |
25 |
Simulated Gastric Fluid, pH 1.2 |
500 |
5, 10, 15 and 30 |
2023/07/07 |
| Deflazacort |
Tablet |
II (Paddle) |
50 |
50 mM Phosphate buffer w/0.3% SLS, pH 6.8 |
500 |
5, ,15, 30 and 45 |
2023/07/07 |